Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence